Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

NAD+ Kinase as a Therapeutic Target in Cancer.

Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR.

Clin Cancer Res. 2016 Nov 1;22(21):5189-5195. Epub 2016 Aug 31. Review.

2.

MTHFD2--a new twist?

Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR.

Oncotarget. 2016 Feb 16;7(7):7368-9. doi: 10.18632/oncotarget.7147. No abstract available.

3.

Functional annotation of rare gene aberration drivers of pancreatic cancer.

Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, Bertino JR, Gingras MC, Ittmann M, Kerrigan J, Chen K, Creighton CJ, Eterovic K, Mills GB, Scott KL.

Nat Commun. 2016 Jan 25;7:10500. doi: 10.1038/ncomms10500.

4.

Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy.

Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, Bertino JR.

Mol Pharmacol. 2015 Oct;88(4):720-7. doi: 10.1124/mol.114.096727. Epub 2015 Jul 28.

5.

Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development.

Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR.

Mol Cancer Res. 2015 Oct;13(10):1361-6. doi: 10.1158/1541-7786.MCR-15-0117. Epub 2015 Jun 22.

6.

Quantification of folate metabolism using transient metabolic flux analysis.

Tedeschi PM, Johnson-Farley N, Lin H, Shelton LM, Ooga T, Mackay G, Van Den Broek N, Bertino JR, Vazquez A.

Cancer Metab. 2015 May 28;3:6. doi: 10.1186/s40170-015-0132-6. eCollection 2015.

7.

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.

Tedeschi PM, Kathari YK, Johnson-Farley N, Bertino JR.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1247-52. doi: 10.1007/s00280-015-2747-2. Epub 2015 Apr 28.

8.

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.

Tedeschi PM, Kathari YK, Farooqi IN, Bertino JR.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1029-32. doi: 10.1007/s00280-014-2580-z. Epub 2014 Sep 9.

9.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Dolfi SC, Chan LL, Qiu J, Tedeschi PM, Bertino JR, Hirshfield KM, Oltvai ZN, Vazquez A.

Cancer Metab. 2013 Nov 7;1(1):20. doi: 10.1186/2049-3002-1-20.

10.

Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.

Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A.

Cell Death Dis. 2013 Oct 24;4:e877. doi: 10.1038/cddis.2013.393.

11.

Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.

Vazquez A, Tedeschi PM, Bertino JR.

Cancer Res. 2013 Jan 15;73(2):478-82. doi: 10.1158/0008-5472.CAN-12-3709. Epub 2012 Nov 7.

Supplemental Content

Loading ...
Support Center